Compare EVGN & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVGN | OSRH |
|---|---|---|
| Founded | 1999 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 12.5M |
| IPO Year | N/A | N/A |
| Metric | EVGN | OSRH |
|---|---|---|
| Price | $1.07 | $0.64 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | 47.3K | ★ 10.2M |
| Earning Date | 11-20-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,016,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.35 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.19 | N/A |
| 52 Week Low | $0.95 | $0.45 |
| 52 Week High | $2.42 | $12.54 |
| Indicator | EVGN | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 49.82 |
| Support Level | $1.03 | $0.60 |
| Resistance Level | $1.19 | $0.77 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 34.62 | 43.00 |
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.